trending Market Intelligence /marketintelligence/en/news-insights/trending/8Z8kLqGP92JABjElBsBaKQ2 content esgSubNav
In This List

Antengene raises $120M to continue development of cancer drugs

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Antengene raises $120M to continue development of cancer drugs

Shanghai-based drug developer Antengene Corp. completed a $120 million series B financing, jointly led by Boyu Capital and FountainVest.

Celgene Corp., WuXi Corporate Venture Fund, Taikang, Qiming Venture Partners and TF Capital participated in the financing, Antengene said in a news release.

The company said it will use the funds to continue developing its lead programs ATG-008, a potential treatment for hematological malignancies and solid tumors, and ATG-010, also known as selinexor, a potential treatment for hepatitis B virus positive hepatocellular carcinoma.

Funds will also be used on Antengene's other clinical-stage assets, as well as expanding its pipeline, through internal research and development and external partnerships, and preparing the commercial launch of late-stage drug candidates.

Antengene is developing anti-cancer drug treatments for patients in China and Asia.